Merck Snaps Up Protiva Technology, Ending Legal Dispute
This article was originally published in The Pink Sheet Daily
Licensing deal removes a preliminary injunction against Sirna RNAi research that Merck also owns.
You may also be interested in...
Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.
Deal comes on the heels of September agreement for potential RNAi therapy for macular degeneration.
Merck continues acquisition spurt with purchase of San Francisco biotech.